Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, September 4, 2024, at 7:45 a.m. E.T. in New York, NY.

Investors and interested parties can access a live webcast of the presentation through the investor relations section of Akero's website at www.akerotx.com. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.

News Market Reaction

+0.98%

1 alert

+0.98% News Effect

On the day this news was published, AKRO gained 0.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 22^nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:45 a.m. E.T. in New York, NY.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com

FAQ

When is Akero Therapeutics (AKRO) presenting at the Morgan Stanley Healthcare Conference?

Akero Therapeutics (AKRO) is presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:45 a.m. E.T. in New York, NY.

How can I watch Akero Therapeutics' (AKRO) presentation at the Morgan Stanley conference?

You can watch a live webcast of Akero Therapeutics' (AKRO) presentation through the investor relations section of the company's website at www.akerotx.com. An archived replay will also be available after the live event.

What type of company is Akero Therapeutics (AKRO)?

Akero Therapeutics (AKRO) is a clinical-stage company that develops treatments for serious metabolic diseases with high unmet medical needs.

Where is the Morgan Stanley Healthcare Conference being held in 2024?

The Morgan Stanley 22nd Annual Global Healthcare Conference, where Akero Therapeutics (AKRO) is presenting, is being held in New York, NY in 2024.